Rashi Peripherals Limited has announced its consolidated financial results for Q3FY26 ended December 31, 2025, demonstrating exceptional performance across key metrics. The company also made significant leadership appointments and strategic expansion moves during the quarter.

Q3FY26 Financial Performance

The company delivered outstanding consolidated financial results for the quarter ended December 31, 2025:

The consolidated revenue of ₹40.00 billion represents a significant increase from ₹28.00 billion in the corresponding quarter of the previous year. Net profit after tax surged to ₹736.00 million compared to ₹318.00 million in Q3FY25. The company's EBITDA performance was particularly impressive, rising to ₹1.20 billion from ₹214.00 million, with margins expanding substantially to 2.95%.

Leadership Appointments

The company announced two key leadership appointments effective February 3, 2026:

Mr. Rajesh Goenka brings over 25 years of experience in sales and marketing, having been associated with the company since 2008. Dr. Indumati Gopinathan is an experienced pathologist with leadership roles in healthcare organizations.

Strategic Expansion and Corporate Actions

The company approved the formation of a step-down subsidiary in UAE, which will be wholly-owned by Rashi Peripherals Pte. Ltd. The new entity, Rashi Peripherals LLC, will have authorized capital of UAE Dirham 1,00,000 with investment up to US$ 5,00,000.

IPO Proceeds Utilization

As of December 31, 2025, the company has substantially utilized its IPO proceeds of ₹554.14 crore, with ₹552.53 crore deployed and only ₹1.61 crore remaining unutilized under General Corporate Purposes. The monitoring agency CARE Ratings Limited reported no deviations in fund utilization during the quarter.

Rashi Peripherals Limited has filed a NIL statement of deviation for its IPO proceeds utilization during Q3FY26 under Regulation 32 of SEBI Listing Regulations. The company confirmed to BSE and NSE on February 3, 2026, that there were no deviations or variations in the utilization of proceeds from its Rs. 600.00 crore Initial Public Offer during the quarter ended December 31, 2025.

Regulatory Compliance and Filing Details

The company submitted the NIL deviation statement to both stock exchanges, with BSE scrip code 544119 and NSE symbol RPTech. The filing was made pursuant to Regulation 32 requirements and was reviewed by the company's Audit Committee in its meeting held on February 3, 2026. Company Secretary and Compliance Officer Arvind Bajoria signed the compliance document, while Chief Financial Officer Himanshu Kumar Shah authenticated the deviation statement.

IPO Proceeds Utilization Status

The monitoring report reveals comprehensive utilization across the three main IPO objects. The company has successfully completed debt repayment and working capital funding, with only General Corporate Purpose showing remaining funds of Rs. 1.61 crore out of the original Rs. 8.14 crore allocation.

Timeline Extension for General Corporate Purpose

The company has extended the utilization timeline for General Corporate Purpose funds through a Board resolution dated April 21, 2025. Originally scheduled for completion by the end of fiscal year 2024, the timeline has been extended to the end of fiscal year 2026 or thereafter. This extension provides flexibility to deploy the remaining Rs. 1.61 crore based on business requirements without requiring shareholder approval as no deviations occurred.

Audit Committee and Monitoring Agency Review

CARE Ratings Limited, serving as the monitoring agency, confirmed that all fund utilization remains consistent with the original offer document disclosures. The Audit Committee reviewed the utilization status and found no material deviations from the disclosed objects. Both the Audit Committee and auditors provided no adverse comments on the IPO proceeds utilization during the quarter.